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Abstract
Background: The control of viral infections in the brain involves the activation of microglial cells, the macrophages
of the brain that are constantly surveying the central nervous system, and the production of amyloid-beta (Aβ) as
an anti-microbial molecule. Recent findings suggest a possible implication of HHV-6A in AD. We evaluated the
effect of HHV-6A infection on microglial cell expression Aβ and the activation status, determined by TREM2, ApoE,
cytokines, and tau expression.
Methods: We have infected microglial cells (HMC3, ATCC®CRL-3304), in monolayer and human peripheral blood
monocyte-derived microglia (PBM-microglia) spheroid 3D model, with HHV-6A (strain U1102) cell-free virus inocula
with 100 genome equivalents per 1 cell. We collected the cells 1, 3, 7, and 14 days post-infection (d.p.i.) and
analyzed them for viral DNA and RNA, ApoE, Aβ (1-40, 1-42), tau, and phospho-tau (Threonine 181) by real-time
immunofluorescence and cytokines by immunoenzymatic assay.
Results: We observed a productive infection by HHV-6A. The expression of Aβ 1-42 increased from 3 d.p.i., while no
significant induction was observed for Aβ 1-40. The HHV-6A infection induced the activation (TREM2, IL-1beta,
ApoE) and migration of microglial cells. The secretion of tau started from 7 d.p.i., with an increasing percentage of
the phosphorylated form.
Conclusions: In conclusion, microglial cells are permissive to HHV-6A infection that induces the expression of Aβ
and an activation status. Meanwhile, we hypothesize a paracrine effect of HHV-6A infection that activates and
induces microglia migration to the site of infection.
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Introduction
Alzheimer’s disease (AD) is multifactorial and character-
ized by early neuronal loss. In AD brains, two pathological
characteristics are observed: extracellular insoluble senile
plaques formed by amyloid-β (Aβ) peptide and intraneur-
onal neurofibrillary tangles (NFT) formed by tau protein
[1]. Aβ, thought to be primarily produced by neurons, can
activate an inflammatory response that ultimately drives
microglia and astrocytes to uptake and clear it from the
brain [2, 3].
The elevation of intracellular soluble Aβ leads to an
abnormal phosphorylation of tau that is relocated from
axons to the somatodendritic compartments of neurons
[4]. Here, tau can bind and sequester the Src tyrosine
kinase, fyn, altering its localization [5] and the phosphor-
ylation and stabilization of excitatory GluN2B NMDA
receptors. This enhances glutamate signaling and causes
an intracellular flood of Ca2+, which enhances Aβ toxicity
[5–7]. Calcium-induced excitotoxicity can damage post-
synaptic sites and cause mitochondrial Ca2+ overload,
membrane depolarization, oxidative stress, and apoptotic
cell death [6, 8].
Interestingly, Aβ plaques and NFT are not unique to
AD. Other central nervous system conditions, including
chronic infections, develop with the production of these
specific histopathologic hallmarks [9]. Recent studies show
the possibility that infections may be associated with AD
and indicate the crucial role of neuroinflammation in the
etiopathogenesis of AD [10, 11]. The inflammatory re-
sponse is a typical reaction during most infectious diseases
that might stimulate activation of microglia, specialized
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macrophages resident in the central nervous system (CNS),
where they remove damaged neurons and infections. Re-
cent findings have shown that infections may induce Aβ
production and deposition in the brain with an anti-
microbial activity [11]. Aβ fibrilization pathway seems to
be an innate immune response that protects against viral,
fungal, and bacterial infections. Aβ oligomers bind herpes-
virus surface glycoproteins, accelerating β-amyloid depos-
ition and leading to protective viral entrapment activity in
5XFAD mouse and 3D human neural cell culture infection
models against neurotropic herpes simplex virus 1 (HSV1)
and human herpesvirus 6A and B [12]. HHV-6 has been
examined for its potential role in AD pathogenesis [10, 13].
Human herpesvirus 6 (HHV-6) is a betaherpesvirus that
exists as two closely related species, HHV-6A and HHV-
6B [14]. HHV-6A has not been etiologically linked to any
disease; HHV-6B is the causative agent of exanthema subi-
tum (ES), a childhood disease characterized by high fever
and a mild skin rash, occasionally complicated by seizures
or encephalitis. The term HHV-6 remains in usage and
collectively refers to the two species. HHV-6 exhibits wide
cell tropism in vivo and, as with other herpesviruses,
induces a lifelong latent infection in humans. HHV-6
preferentially replicates in activated CD4+ T lymphocytes
[15, 16] and uses specific cell receptors permitting virus
anchorage to the cell surface: HHV-6A uses CD46, a regu-
lator of complement activation expressed on all nucleated
cells, while CD134 (also called OX40), a member of the
tumor necrosis factor (TNF) receptor superfamily present
only on activated T lymphocytes, functions as a specific
entry receptor for HHV-6B [17, 18]. In vitro experimenta-
tion has shown that in addition to CD4+ T lymphocytes,
HHV-6 can infect CD8+ T lymphocytes (only with HHV-
6A), fibroblasts, natural killer (NK) cells [19], liver cells,
epithelial cells, endothelial cells, microglial cells, astrocytes,
and oligodendrocytes [15, 19–26]. The in vivo host tissue
range appears to be broader than expected from in vitro
studies and includes the brain, salivary glands, tonsils, kid-
neys, lymph nodes, liver, heart, gastrointestinal tract, lungs,
and monocytes/macrophages [15, 27–29]. The preferential
sites for latency are suspected to be monocytes/macro-
phages, bone marrow progenitors, and central nervous
system cells [30–32]. Fecal-oral spread, a common trans-
mission route among young children, has not been docu-
mented for HHV-6, although stool specimens were found
positive for HHV-6 DNA [33]. Thus, the most probable
route for HHV-6B transmission is through saliva [34]. Very
little is known about the epidemiology of HHV-6A, which
is acquired later in life, is not typically found in the saliva,
and has an unknown mechanism of transmission. Inter-
estingly, HHV-6 DNA can be integrated into the subte-
lomeric region of host chromosomes as an inherited,
chromosomally integrated HHV-6 variant (iciHHV-6),
which is present in about 1% of the general population
and is passed through generations via vertical transmis-
sion [35].
Carbone and colleagues analyzed DNA isolated from
PBL and brain samples for the presence of EBV, HHV-6,
and CMV [36]. DNA of HSV1, EBV, and HHV-6, but
not CMV, was found. Interestingly, HHV-6 was found in
70% of AD brains vs 40% of controls, while HSV-1 was
found at high levels in both. In this prospective study,
increases in EBV-positive or HHV-6-positive PBL were
noted in patients who developed clinical AD. Readhead
and co-authors have determined that genes involved
with AD overlap with those involved in fighting viral
infection [10]. They found HHV-6A and HHV-7 to be
more abundant in Alzheimer’s brains and singled out
HHV-6A as a key modulator of the genes involved in
amyloidosis and neuronal death. HHV-6A and HHV-7
DNA transcription was increased among AD patients,
and this was observed across multiple brain regions and
multiple cohorts with a lower abundance in healthy
aging controls. Host genes affected by HHV-6A were
associated with Alzheimer’s traits and risk genes. Also,
HHV-6A correlated strongly with dementia scores, neur-
onal death, and intensity of amyloid plaque.
On the one hand, Aβ neuritic plaques are surrounded
by activated microglial cells that could contribute to Aβ
phagocytosis and/or compaction [37, 38]. On the other
hand, HHV-6A infection might induce Aβ deposition as
an innate immune response. Since the major cell com-
ponent with a role in innate immune response in the
brain, we aimed to evaluate the effect of HHV-6A infec-
tion on microglia status. In particular, we will evaluate if
HHV-6A infection induces Aβ also in microglial cells
and the effect on their activation status. Microglial acti-
vation and survival are associated with the expression of
different molecules as triggering receptor expressed in
myeloid cells 2 (TREM2) that seems to perform a pivotal
role in the AD-associated immune response [39, 40].
TREM2 is a lipid and lipoprotein sensor that, through
its adapter molecule DAP12, supports reactive micro-
gliosis [41]. Furthermore, it has been recently demon-
strated that TREM2, interacting with apolipoprotein E
(ApoE—a major genetic risk factor for AD), regulates
the transcriptional activation of microglial cells [42].
Meanwhile, the expression of tau by microglia cells
themselves was also shown to promote their activation
[43]. It was found that the expression of tau promoted
microglia migration and phagocytosis, and the secretion
of several cytokines, including interleukin (IL)-1β, IL-6,
IL-10, and tumor necrosis factor-α, suggesting a role of
tau in microglial activation. An inappropriate immune
response in the brain may be engaged in the neurodes-
tructive processes involved in AD [44]. In fact, chronic
microglial activation could improve AD pathology by re-
ducing the Aβ levels in APP-based models. However, the
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inflammatory response associated with glial activation
has been associated with detrimental neurotoxic effects
mediated by the release of pro-inflammatory cytokines/
chemokines and neurotoxins [45–47]. Increasing patho-
logical Aβ deposits activate glial cells (microglia and as-
trocytes), lymphocytes, and macrophages, which in turn
release large amounts of inflammatory mediators such as
cytokines, chemokines, neurotransmitters, and reactive
oxygen species (ROS) [48]. Reactive microglia and astro-
cytes induce neuronal apoptosis and blood-brain barrier
(BBB) dysfunction. Next, this process leads to the re-
cruitment of peripheral blood leukocytes (PBL) through
the BBB and their active participation in local inflammation
in the brain tissue. Leukocytes release more inflammatory
factors (cytokines), escalate the inflammatory state, and
exacerbate other AD pathologies [49].
We will analyze the effect of HHV-6A infection on
microglial cell status, evaluating the expression of genes as-
sociated with microglial activation and AD pathogenesis.
The identification of an association between HHV-6A
infection and microglial cell status in AD would set the
stage for new therapeutic interventions. A positive find-
ing would also lead to a better understanding of the role
of microbiota in AD, allowing our study to serve as a
“springboard” to a more general use of anti-microbial or
immunomodulatory therapies in AD practice.
Materials and methods
Study subjects
We recruited five healthy members of societies for
retired people for the cognitively normal control group.
Only ethnic Italians without known dementia in first de-
gree relatives were included. The study was approved by
the Ethics Committee of the University of Ferrara, and
the subjects consented to the study in accordance with
the Declaration of Helsinki.
Peripheral blood monocyte-derived microglia
To obtain monocytes (adherent PBMC), the isolated
blood cells were cultured in T25 tissue culture flasks
(2 × 10^6 to 5 × 10^6 cells/ml) using RPMI-1640 Gluta-
max medium (Invitrgen, Italy) supplemented with 1%
antibiotics/antimycotic (10,000 units/ml penicillin G so-
dium, 10,000 g/ml streptomycin sulfate, and 25 g/ml
Amphotericin B, Invitrogen). After overnight incubation,
non-adherent cells will be separated by washing with
PBS (Invitrogen) and the fresh adherent cells, which are
mainly monocytes (> 90%), will be used for the gener-
ation of microglia (M-MG). To induce the differentiation
of PBM-microglia, adherent PB will be cultured in 6-well
tissue culture plates (Sarstedt; Germany) using RPMI-1640
Glutamax supplemented with1% antibiotic/antimycotic
(serum-free condition) and a mixture of human recombin-
ant cytokines, including M-CSF (10 ng/ml; PeproTech,
USA), GM-CSF (10 ng/ml; PeproTech), beta-nerve growth
factor (NGF-beta 10 ng/ml; PeproTech), and CCL2 (100
ng/ml) for up to 14 day. The generation of PBM-microglia
was confirmed by morphology evaluation and immune-
phenotype characterization for the expression of substance
P with anti-substance P FITC mouse monoclonal anti-
bodies (mAb) and induced the expression of Iba1 by anti-
Iba-1 PE mAb [50].
3D cultures: microglial spheroid generation
PBM-microglia were seeded in 96-well plate coated with
1.5% agarose to allow the spheroid formation. The micro-
glial spheroids had a 100–250-μm-diameter spheroid at
2–4 days of culture, using 3 × 104 cells/ml medium [51].
Then, spheroids were picked up, transferred into new
wells, and used for further experiments.
HHV-6 infection
The human T cell line J-Jhan was cultured in RPMI-
1640 (Gibco BRL, Invitrogen Corporation, Carlsbad, CA,
USA) with 10% FCS supplemented with 100 U/ml each
of penicillin and streptomycin and maintained at 37 °C
in humidified atmosphere of 5% CO2. The human im-
mortalized microglial cell line human microglial clone 3
cell line, HMC3, (ATCC®CRL-3304) was maintained in
EMEM supplemented with 10% fetal bovine serum
supplemented with 100 U/ml each of penicillin and
streptomycin and maintained at 37 °C in humidified
atmosphere of 5% CO2. J-Jhan and HMC3 cells were
infected with a HHV-6A (U1102) cell-free inoculum as
previously described [52] at a 100:1 m.o.i. The cells were
harvested at the experimental time point to perform the
analysis.
HHV-6 analysis
HHV-6 DNA viral load was analyzed by real-time quan-
titative (qPCR) in duplicate, as described [19].
RNA cell extraction was performed using the RNeasy kit
(Qiagen, Hilden, Germany). No DNA contaminated the
RNA samples, as shown by control β-actin PCR without ret-
rotranscription [53]. Reverse transcription was performed by
the RT2 First strand kit (Qiagen, Hilden, Germany). cDNA
aliquots corresponding to 200 ng RNA were used for virus
transcription analysis, performed by qPCR detecting the ex-
pression of U42 gene, as previously reported [52].
Immunofluorescence assay
Immunofluorescence for HHV-6 antigen expression was
performed with a mAb against glycoprotein gp116 (late
antigen) of HHV-6 A and B (ABI, Columbia, MD, USA),
as previously described [53]. Microglial cells were stained
with anti-substance P FITC (NC1/34HL) mAb anti-Iba-1
PE (1022-5) mAb, anti-TREM2 PE mAb (B-3) (Santa Cruz
Biotechnology, USA), anti-Aβ 1-40 (NBP1-44047; Novus
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Biologicals; Italy), and Aβ 1-42 moAb (ab10148; Abcam;
UK).
APOE and TREM2 expression
Microglial cells, infected with HHV-6A (U1102), were
harvested after 1, 3, 7, and 14 days post-infection. Total
RNA was extracted (RNeasy kit, Qiagen, Hilden,
Germany) and checked for the absence of contaminating
DNA and for RNA integrity, and we analyzed only the
samples with RIN > 8. RNA reverse transcription was
performed as described above. ApoE and TREM2 ex-
pression analysis was performed on DNA aliquots corre-
sponding to 200 ng RNA using Applied Biosystems gene
expression analysis (Hs00171168_m1 and Hs01003898_
m1, respectively) [54].
Cytokine ELISA assay
IL-1α, IL-1β, IL-6, IL-10, and tumor necrosis factor-α
levels in microglial culture supernatants were evaluated
by single ELISA kit assays (myBiosource, USA) following
the customer’s protocols.
Tau ELISA assay
Total tau and phosphorylated (p) tau (Threonine 181,
T181) were analyzed by ELISA assay (KHB0041 and
KHO0631, respectively; Invitrogen; Italy) on cell lysates.
Briefly, cell lysates were obtained using a specific lysis
buffer prepared adding to RIPA Buffer 1X protease in-
hibitor cocktail (Roche; Italy), 1% Triton X-100 (Sigma),
1% sodium orthovanadate (Sigma; UK), and 1% PMSF
(Sigma). Cell lysates were quantified by the Bradford
assay (Biorad; Italy), and then, 20 μg of the total lysate
was diluted in 50 or 100 μl of the specific ELISA diluent
and seeded into pre-coated wells. The presence of both
total tau and ptau (T181) in the samples was revealed by
colorimetric reaction and read at 450 nm, and concen-
tration determined through interpolation to standard
curve and reported as picograms per milliliter.
Cell migration assay system
Test J-Jhan cells were plated on the bottom wells (2 ×
105 cells/well) of 24 multiwell plates (Falcon; USA) into
which FluoroBlock cell culture inserts (BD Biosciences;
USA) were to be inserted. These inserts are designed for
the plating of cells on a membrane which contains pores
of defined size. The base of the membrane blocks all
fluorescence transmission, such that when using live cell
fluorescence analysis with an inverted microscope, any
fluorescence signal originates only from cells that mi-
grated through the pores onto the bottom side of the
membrane. We used 8 μm pores. The bottom cell mono-
layers in the 24-well plates were mock infected or
infected with HHV-6A (U1102) cell-free inoculum as
previously described [52] at a 100:1 m.o.i. After 1 h of
adsorption in serum-free media, the inoculum was
removed, and medium containing 2% FBS was added.
The inserts, which had been separately plated with
HMC3 cells, pre-stained with Syto9 label (Thermo
Fisher Scientific; Italy), at a density of 2 × 104 cells/insert,
were then placed into the 24-well plates containing the
mock infected or infected monolayers. At different times
after initial infection, the inserts were removed and ana-
lyzed by fluorescence microscopy. Average total Syto 9
staining (pixel density) of target cells after thresholding
removed the defined background signal. Values were
obtained from three random low-power fields for each
condition in each of the duplicated samples.
Statistical analysis
Data were analyzed by using Student’s t test (Stat View
software (SAS Institute Inc)). Statistical significance was
assumed for p < 0.05 (two tailed).
Data availability
Data are available upon request.
Results
Microglial cells are permissive to HHV-6A infection
We evaluated the ability of HHV-6A to infect microglial
cells. Microglia were seeded at 60–70% confluence and
infected with HHV-6A cell-free inoculum with a m.o.i.
of 100:1. HHV-6A infection was evaluated at 1, 3, 7, and
14 days post-infection (d.p.i.) by performing RT-qPCR
for immediate early (IE) U42 viral mRNA and immuno-
fluorescent staining for the expression of HHV-6A
gp116 late viral antigen. As shown in Fig. 1a, we ob-
served an increase in U42 IE viral gene expression that is
maintained during the 14 d.p.i. Similarly, the immuno-
fluorescence of gp116 confirmed microglial permissivity
to HHV-6A infection (Fig. 1b). The results obtained by
gp116 immunofluorescence showed a temporal shift
with respect to RT-qPCR data on the IE viral gene, due
to the time lapse between IE and late gene expression.
HHV-6A infection of microglial cells induces beta-amyloid
expression
Aβ is the major constituent of neural plaques, representing
one of the more important molecules associated with AD
pathogenesis. It has been shown that the presence of HSV-1
and HHV-6 rapidly induces amyloid plaque production
within 24 to 48 h [11, 55]. These results support the hypoth-
esis that Aβ deposition and fibrillization might be an innate
immune response to pathogens which could protect the
brain under normal circumstances. For this reason, we eval-
uated the effect of HHV-6A on the expression of the two
Aβ isoforms more associated with AD (Aβ1-40 and Aβ1-
42) [56]. We observed increased expression of Aβ1-42 and
a slight increase in expression of Aβ1-40 during HHV-6A
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infection (Fig. 2a). Interestingly, the immunofluorescence
analysis showed a co-localization of gp116 late viral antigen
with Aβ1-42 protein expression (Fig. 2b), suggesting a dir-
ect effect of HHV-6A infection on Aβ1-42 induction.
As a proof of principle, we infected spheroid 3D models,
which were created using PBM-microglial cells from
healthy subjects, with HHV-6A. We characterized the
PBM-microglia, evaluating the levels of substance P (known
to exacerbate neuroinflammation) and Iba-1 (ionized cal-
cium binding adaptor molecule 1; a microglia-specific
marker). We observed an increased expression of both sub-
stance P and intracellular Iba-1, suggestive of microglial
phenotype (Additional file 1: Figure S1A).
HHV-6A spheroid infection was monitored by gp116
expression. We confirmed the permissivity of microglial
cells to HHV-6A infection, as documented by the in-
creased transcription of the U42 IE viral gene and the ex-
pression of gp116 late viral antigen (Fig. 2c–e). Analysis
also showed increased Aβ1-42 expression (Fig. 2d) follow-
ing the increase in gp116 expression. Interestingly, with a
higher magnification, it is possible to observe Aβ depos-
ition, which is evident at 14 d.p.i. (Fig. 2e, left panel).
HHV-6A infection induces microglia activation status
Microglial activation status might be induced by HHV-
6A infection. We evaluated the expression of TREM2, a
marker of microglial reactive status, in microglial cells
infected with HHV-6A. We observed a significant in-
crease in TREM2 expression, with a 40-fold increase at
14 d.p.i. (Fig. 3a, b). Since it has been recently demon-
strated that TREM2, interacting with ApoE, regulates
the transcriptional activation of microglial cells [42], we
analyzed also ApoE expression in microglial cells.
Figure 1c shows that HHV-6A infection also induces
ApoE expression in microglial cells. The increase in
ApoE expression was 2-fold at 3 d.p.i. and reached a 45-
fold increase at 14 d.p.i. The evaluation of pro-
inflammatory and anti-inflammatory cytokines (IL-1α,
IL-1β, IL-6, IL-10, tumor necrosis factor-α) showed a
significant decrease in IL-10 expression (p = 0.012; Stu-
dent’s t test) and an increase in IL-1beta expression (p <
0.001; Student’s t test) (Fig. 3c). Since IL-1beta is detect-
able at abnormal levels in AD, with a dose-dependent
correlation between ApoE and the levels of pro-
inflammatory cytokines [57], we correlated IL-1beta and
ApoE expression with HHV-6A infection. The analysis
of IL-1beta expression showed a significant increase dur-
ing HHV-6A infection, with a 2-fold increase at 3 d.p.i.,
after which it plateaued (Fig. 3a). During the first 6 d.p.i.,
the IL-1beta expression followed ApoE increase (Fig. 3a).
HHV-6A infection of microglial cells induces tau
phosphorylation
Tau is one of the microtubule-associated proteins that
regulate the stability of tubulin assemblies. In AD brains,
tau is accumulated in a hyper-phosphorylated state in the
pathological inclusions [58, 59]. The expression of tau by
microglial cells themselves was also shown to promote their
activation and secretion of several cytokines [43]. We inves-
tigated total-tau and p-tau (T181) levels in healthy donor
PBM-microglial cells infected with HHV-6A. HHV-6A
infection was associated with an increase of both total-tau
(Fig. 4a, p < 0.0001, Student’s t test) and p-tau (T181) (Fig.
4b, p < 0.0001, Student’s t test), particularly 7 and 14 d.p.i.
HHV-6A infection induces microglial cell migration
Using a cell migration assay system (see the “Materials and
methods” section), we assessed whether there was evidence
that HHV-6A infection could induce microglial cell migra-
tion at the site of infection. Target microglial cells were
plated in the upper chamber insert on a membrane support
with defined 8-μm pores (Fig. 5a). The insert was then
Fig. 1 HHV-6A infection of microglial cells. a Microglial cells were infected at a multiplicity of infection of 100 genome equivalent/cell. Virus
transcription (RNA) was evaluated by RT-qPCR performed on the U42 virus gene, at 1, 3, 7, and 14 d.p.i., as already detailed. Results are expressed
in log target molecules referred to duplicates of 2 independent assays. b HHV-6A-infected microglial cells (m.o.i. 100:1; 1, 3, 7, 14 d.p.i.) were
stained with Hoechst and anti-gp116 FITC moAb. Images were taken in fluorescence (Nikon Eclipse TE2000S) equipped with a digital camera.
Original magnification × 20
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placed in a dish of test cells (lower chamber) that were ei-
ther mock infected or infected with 100:1m.o.i. We con-
firmed that the upper target cells remained uninfected
(Additional file 1: Figure S1B). Cell migration was then
monitored by the presence of cells on the lower side of
the membrane support by live cell staining. The results
demonstrated a very clear increase in target cell migration
with infected test cells compared to uninfected test cells
(Fig. 5b, c). This could be readily seen in the images of tar-
get cell migration (Fig. 5b) and in the quantitation of the
Fig. 2 Beta amyloid expression in HHV-6-infected microglial cells. a Expression of the two Abeta isoforms more associated to AD (Aβ1-40 and
Aβ1-42) was evaluated in monolayer microglial cells infected at a multiplicity of infection of 100 genome equivalent/cell at 1, 3, 7, and 14 d.p.i.
The results are reported as percentage of the isoform on the total expression. b HHV-6A-infected microglial cells (m.o.i. 100:1; 3, 14 d.p.i.) were
stained with Hoechst, anti-gp116 FITC, and anti Abeta 1-42 PE moAbs. Images were taken in fluorescence (Nikon Eclipse TE2000S) equipped with
a digital camera. Original magnification × 20. Spheroid 3D models obtained with PBM-microglial cells from healthy subjects. c Microglial cells
were infected at a multiplicity of infection of 100 genome equivalent/cell. Virus transcription (RNA) was evaluated by RT-qPCR performed on U42
virus gene, at 1, 3, 7, and 14 d.p.i., as already detailed. Results are expressed in log target molecules referred to duplicates of 2 independent
assays. d Expression of Aβ1-42 and gp116 was evaluated in spheroid 3D microglial cells infected at a multiplicity of infection of 100 genome
equivalent/cell at 1, 3, 7, and 14 d.p.i. The results are reported as percentage of the isoform on the total expression. e HHV-6A-infected spheroid
3D microglial cells (m.o.i. 100:1; 3; 14 d.p.i.) [14] were stained with Hoechst, anti-gp116 FITC, and anti Abeta 1-42 PE moAbs. Images were taken in
fluorescence (Nikon Eclipse TE2000S) equipped with a digital camera. Original magnification: × 20, left panels; × 40, right panels
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Fig. 3 a mRNA apoE, IL-1beta, and TREM2 expression was evaluated in microglial cells at 1, 3, 7, and 14 d.p.i. b HHV-6A-infected microglial cells
(m.o.i. 100:1; 14 d.p.i.) were stained with anti-Iba-1 FITC and TREM2 PE moAbs. Images were taken in bright field (left panel) or fluorescence (right
panels) (Nikon Eclipse TE2000S) equipped with a digital camera. Original magnification × 20. c IL-1α, IL-1β, IL-6, IL-10, and tumor necrosis factor-α
expression in uninfected (white histogram) and in HHV-6-infected microglial cells (gray histogram). *p value < 0.0001, obtained by Student’s t test.
Each experiment was performed in triplicate
Fig. 4 Tau and phosphorylated tau (ptau) expression in HHV-6-infected microglial cells. a Expression of tau and b phosphorylated tau (ptau) was
evaluated in monolayer microglial cells infected at a multiplicity of infection of 100 genome equivalent/cell at 1, 3, 7, and 14 d.p.i. The results are
reported as mean ± SD pg/ml. *p value < 0.01, obtained by Student’s t test. Each experiment was performed in triplicate
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data (Fig. 5c). Identical results were obtained in repeated
experiments and in experiments using inserts with a 3-μm
pore size instead of 8 μm (data not shown). This system
suggests a paracrine effect of HHV-6A infection, since the
cells are not in direct contact with one another.
Discussion
There is increasing evidence of a possible role for viral in-
fections in the progression of AD, in addition to known
risk factors. To date, the most studied viruses in correl-
ation to AD development are herpesviruses [60], since
they have the ability to undergo latency and then reacti-
vate, causing persistent infection and neuroinflammation,
which is observed in AD [61]. Recent findings have shown
that infections may induce Aβ production and deposition
in the brain with an anti-microbial activity [11]. Aβ fibrili-
zation pathway seems to be an innate immune response
that protects against viral, fungal, and bacterial infections.
Aβ oligomers bind herpesvirus surface glycoproteins, ac-
celerating β-amyloid deposition and leading to protective
viral entrapment activity [11, 12]. One such infection is
that of HHV-6, which has been examined for its potential
role in AD pathogenesis [10, 13].
The aim of this study was to evaluate the role of HHV-6A
infection of CNS accessory cells (microglia) in AD patho-
genesis. We developed an in vitro model of the human
microglial cells, using both monolayer and spheroid cultures,
in order to evaluate the effects of HHV-6A infection on Aβ
expression and on activation status.
HHV-6A can productively infect microglial cells both
in monolayer and spheroid conformation, as confirmed
by the increased transcription and expression of viral
proteins (Figs. 1a; 2c, e; and 3a).
HHV-6A predominantly induces expression of Aβ1-42
(Fig. 2a, b), which is co-localized with HHV-6A infection
sites (Fig. 2b). The recent discovery that Aβ is an anti-
microbial peptide (AMP) acting against bacteria, fungi,
and viruses gives increased credence to an infection hy-
pothesis in the etiology of AD [62–64]. The production
of Aβ as an AMP will be beneficial on first microbial
challenge but will become progressively detrimental as
the infection becomes chronic and reactivates from time
to time [65]. It has been shown that HSV-1 and HHV-6
catalyze the aggregation of the amyloid β-peptide
(Aβ42), a major constituent of amyloid plaques in Alz-
heimer’s disease, in vitro and in animal models. The viral
protein corona seems to be critical for viral-host interac-
tions and illustrates a mechanistic convergence between
viral and amyloid pathologies [55].
HHV-6A infection induced the activation of microglial
cells as shown by the increased expression of TREM2. It is
already known that a soluble form of TREM2 (sTREM2)
derived from proteolytic cleavage of the cell surface recep-
tor is increased in the preclinical stages of AD, positively
Fig. 5 Cell migration of HHV-6-infected microglial cells. a Cell migration assay system where target microglial cells were plated in the upper chamber
insert on a membrane support with defined 8-μm pores. The insert was then placed in a dish of test cells (lower chamber) that were either mock
infected or infected with 100:1m.o.i. b Representative images of target microglial cells stained with Syto 9. c Average total Syto 9 staining (pixel
density) of target cells after thresholding to remove the defined background signal (image in Fig. 4b). Values were obtained from three random low-
power fields for each condition in each of the duplicated samples. The experiment was repeated three times with similar results
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correlates with the amounts of total and phosphorylated
tau in the cerebrospinal fluid, promotes microglial survival
in a PI3K/Akt-dependent manner, and stimulates the pro-
duction of inflammatory cytokines depending on NF-κB.
The TREM2-ApoE pathway is important for facilitating
the microglial response to damage in the brain, and a func-
tional consequence of activation of the TREM2-ApoE
pathway is that microglia lose the ability to regulate brain
homeostasis [42]. Previous studies suggested a link be-
tween virus-perturbed lipids and TREM2 that modulates
pathogenesis upon viral infection [66], suggesting a pos-
sible link between the ApoE-TREM2 pathway and activa-
tion of HHV-6A-infected microglial cells. We observed a
significant increase in ApoE expression 3 d.p.i. (Fig. 3a),
confirming our previous data on ApoE [54]. Similarly, we
observed an increase in IL-1beta expression, suggesting the
involvement of HHV-6A in microglial activation and IL-
1beta secretion, which may be involved in the induction of
CNS neuroinflammation in AD [60]. Many studies now
point to the involvement of neuroinflammation playing a
fundamental role in the progression of the neuropatho-
logical changes that are observed in AD [67], where IL-1
elevated levels seem to be responsible for the increased
APP production and Aβ load [68]. Meanwhile, Parajuli and
coauthors described that soluble oligomeric amyloid-β
(oAβ) increased the processing of pro-IL-1β into mature
IL-1β in microglia via ROS-dependent activation of NLRP3
inflammation [69]. In addition, Aβ has been reported to ac-
tivate microglia, leading to increased synthesis and release
of neurotoxic secretory products, pro-inflammatory cyto-
kines such as IL-1β, and ROS [70]. Based on these findings,
we can hypothesize a feedback loop between Aβ deposits
and IL-1β expression in AD patients.
The analysis of total-tau and p-tau (T181) showed an
increase in both total and phosphorylated proteins in the
presence of HHV-6A infection. It has been previously
shown that viral infection-induced acute or chronic in-
flammation significantly exacerbates tau pathological
characteristics, and that the chronic inflammation leads
to impaired spatial memory in mice [71].
HHV-6A infection can induce microglial cell migration
to the site of infection. We believe these results indicate
that HHV-6A-infected cells release a soluble mediator that
can stimulate microglial cell migration. This paracrine ef-
fect of HHV-6A infection might in part explain the activa-
tion status of microglial cells in AD patients. Microglia, the
resident innate immune cells in the brain, have long been
implicated in the pathology of neurodegenerative diseases
[72]. Accumulating evidence points to activated microglia
as a chronic source of multiple neurotoxic factors, includ-
ing IL-1beta, driving progressive neuron damage. Microglia
can become chronically activated by stimuli (e.g., HHV-6A
infection), resulting in chronic neuroinflammation exacer-
bated by the TREM2-ApoE pathway and IL-1beta
expression. Interestingly, Liddelow and coauthors showed
that the activation of microglia might precede the activation
of astrocytes, which in turn appear to be responsible for
neuronal cell death [73].
Conclusions
In conclusion, this study showed the permissivity of micro-
glial cells to HHV-6A infection, supporting the hypothesis
of HHV-6A involvement in AD pathogenesis. Its ability to
induce Aβ1-42 supports the role of this molecule as anti-
microbial agent. TREM2, ApoE, IL-1beta, and p-tau (T181)
are suggestive of a direct effect of HHV-6A infection on
microglial cell activation that should be evaluated carefully.
Moreover, the ability of HHV-6A infection to induce mi-
gration of microglial cells strengthens the hypothesis of
HHV-6A playing an important role in AD. Further studies
on the mechanism at the basis of HHV-6A-mediated con-
trol of the microglial gene expression profile are needed to
identify potential antiviral therapies for AD management.
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